One example of this has been reported in tumorspheres from the breast cancer cell line BT474, in which upregulation of HER2 expression led to a hypoxia-conditioned breast CSCs population with increased resistance to trastuzumab26. The gene discussed is ERBB2; the disease is breast carcinoma.